Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A total of 335 patients with early Parkinson's disease (PD) were enrolled in a multicenter, randomized, double-blind trial designed to assess the efficacy and safety of pramipexole. Entry was restricted to patients with idiopathic PD who were not receiving levodopa. Pramipexole was administered according to an ascending dose schedule up to 4.5 mg/d. During the 7-week dose-escalation phase, each subject was titrated to his or her maximally tolerated dose of study medication. This was followed by a 24-week period of maintenance therapy. The mean daily dose during the maintenance period was 3.8 mg. Pramipexole significantly reduced the severity of PD symptoms and signs compared with placebo, as measured by decreases in parts II (Activities of Daily Living) and III (Motor Examination) of the Unified Parkinson's Disease Rating Scale at week 24 compared with baseline (p < or = 0.0001). Differences between the active drug and placebo groups emerged at week 3 (1.5 mg/d) in the ascending-dose interval and persisted throughout the maintenance phase (p < or = 0.0001). The majority of patients completed the study (pramipexole 83%, placebo 80%). In the assessment of adverse events, nausea, insomnia, constipation, somnolence, and visual hallucinations occurred more frequently in the pramipexole treatment group compared with placebo patients. No clinically significant changes were noted in blood pressure or pulse rate. Overall, these results indicate that pramipexole is safe and effective in the treatment of early PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,613
Status epilepticus: epidemiologic considerations.
Hauser, W. A. (1990) · PubMed · Cited by 351
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors
Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E., & Huff, R. M. (1995) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(95)90013-6 · Cited by 257
The rationale for the use of dopamine agonists in Parkinson's disease
Jenner, P. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s6 · Cited by 149
Dopamine agonists in Parkinson's disease
Wolters, E. C., Tissingh, G., Bergmans, P., & Kuiper, M. A. (1995) · Neurology · doi:10.1212/wnl.45.3_suppl_3.s28 · Cited by 60
Chekhov: playwright and physician
(1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.1.7 · Cited by 22
Receptors for gammaglobulin in the central and peripheral nervous system.
Vedeler, C. A., Ulvestad, E., Nyland, H., Matre, R., & Aarli, J. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.9 · Cited by 19
Cited by
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., & Fahn, S. (1999) · Neurology · doi:10.1212/wnl.52.9.1908 · Cited by 692
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
A Controlled Trial of Rasagiline in Early Parkinson Disease: The TEMPO Study
(2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1937 · Cited by 579
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Shulman, L. M., Gruber-Baldini, A. L., Anderson, K. E., Fishman, P. S., Reich, S. G., & Weiner, W. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.295 · Cited by 494
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Deleu, D., Northway, M. G., & Hanssens, Y. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00003 · Cited by 349
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Epidemiology of psychosis in Parkinson's disease
Fénelon, G., & Alves, G. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.014 · Cited by 330
Minimal clinically important change on the unified Parkinson's disease rating scale
Schrag, A., Sampaio, C., Counsell, N., & Poewe, W. (2006) · Movement Disorders · doi:10.1002/mds.20914 · Cited by 297
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Treatment interventions for Parkinson's disease: an evidence based assessment
Rascol, O., Goetz, C., Koller, W., Poewe, W., & Sampaio, C. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08520-3 · Cited by 279
Energy metabolism in ALS: an underappreciated opportunity?
Vandoorne, T., De Bock, K., & Van Den Bosch, L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1835-x · Cited by 262
Barone, P., Scarzella, L., Marconi, R., Antonini, A., Morgante, L., Bracco, F., Zappia, M., Musch, B., & and the Depression/Parkinson Italian Study Group (2006) · Journal of Neurology · doi:10.1007/s00415-006-0067-5 · Cited by 248
“Clinical trials have shown it to be effective in treating motor symptoms of PD [15, 17, 22].”
BackgroundThe Pathophysiology of Fatigue in Parkinson's Disease and its Pragmatic Management
Kostić, V. S., Tomić, A., & Ječmenica‐Lukić, M. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12343 · Cited by 78
Metadata
- Authors
- Shannon, K. M., Bennett, J. P., Friedman, J. H., & the Pramipexole Study Group
- Venue
- Neurology
- Published
- 1997-09
- Volume
- 49
- Issue
- 3
- Pages
- 724-728
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2165370634
- Cited by
- 281
- References
- 7
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.